Co-Diagnostics adjourns 2026 shareholder meeting
Co-Diagnostics, Inc. adjourned its 2026 Annual Meeting for lack of quorum and rescheduled it for September 24, 2026 at its Salt Lake City offices.
Rhea-AI Filing Summary
Co-Diagnostics, Inc. (CODX) reported that its September 3, 2026 Annual Meeting of Stockholders did not achieve a quorum, so no business could be conducted. Under the company’s bylaws, the chairperson adjourned the meeting.
The Annual Meeting is adjourned to September 24, 2026 at 9:00 a.m. Mountain Time, to be held at the company’s offices at 2401 S. Foothill Dr, Ste. D, Salt Lake City, Utah 84109. Stockholders may participate and vote as described in the definitive proxy statement filed on July 21, 2026, and all valid proxies already submitted will remain effective for the reconvened meeting unless changed or revoked before votes are taken.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Initial Annual Meeting date: September 3, 2026
Adjourned Annual Meeting date and time: September 24, 2026, 9:00 a.m. Mountain Time
Meeting location: 2401 S. Foothill Dr, Ste. D, Salt Lake City, Utah 84109
+1 more
4 metrics
Initial Annual Meeting date
September 3, 2026
Date on which the 2026 Annual Meeting was convened but lacked a quorum
Adjourned Annual Meeting date and time
September 24, 2026, 9:00 a.m. Mountain Time
Scheduled time for the reconvened 2026 Annual Meeting
Meeting location
2401 S. Foothill Dr, Ste. D, Salt Lake City, Utah 84109
Offices of Co-Diagnostics where the adjourned Annual Meeting will be held
Definitive proxy statement filing date
July 21, 2026
Filing date of the proxy statement governing procedures for the Annual Meeting
Key Terms
quorum, Annual Meeting of Stockholders, bylaws, definitive proxy statement
4 terms
quorum regulatory
"the Company did not achieve a quorum and therefore was unable to transact"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
Annual Meeting of Stockholders regulatory
"held its previously announced Annual Meeting of Stockholders (the “Annual Meeting”)"
bylaws regulatory
"Pursuant to the Company’s bylaws, if a quorum is not present"
Corporate bylaws are a company's internal rulebook that explains how the business is run day to day — who makes decisions, how directors and officers are chosen, how shareholder meetings are conducted, and procedures for changes or conflicts. For investors, bylaws matter because they shape governance and control, influence how quickly and easily leadership or strategy can change, and can protect or limit shareholder rights much like house rules affect how a household operates.
definitive proxy statement regulatory
"in the same manner as disclosed in the definitive proxy statement"
A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.
FAQ
Why did Co-Diagnostics, Inc. (CODX) adjourn its September 3, 2026 Annual Meeting?
The Annual Meeting on September 3, 2026 was adjourned because a quorum was not achieved, so the company could not transact any business. Under its bylaws, the chairperson had authority to adjourn the meeting until a quorum is present or represented.
When and where will CODX hold the reconvened 2026 Annual Meeting?
The adjourned Annual Meeting is scheduled for September 24, 2026 at 9:00 a.m. Mountain Time, at Co-Diagnostics’ offices at 2401 S. Foothill Dr, Ste. D, Salt Lake City, Utah 84109.
Are previously submitted proxies for CODX’s 2026 Annual Meeting still valid?
Yes. Valid proxies submitted before the reconvened Annual Meeting will remain valid for the September 24, 2026 meeting, unless they are properly changed or revoked before votes are taken at the reconvened Annual Meeting.
How will CODX stockholders be deemed present and able to vote at the reconvened meeting?
At the adjourned Annual Meeting on September 24, 2026, stockholders will be deemed present in person and able to vote in the same manner as disclosed in the definitive proxy statement filed on July 21, 2026.
What procedural rule allowed CODX to adjourn the 2026 Annual Meeting without further notice?
Under Co-Diagnostics’ bylaws, if a quorum is not present or represented at a stockholder meeting, the chairperson may adjourn the meeting from time to time without notice other than announcement at the meeting, until a quorum is present or represented.
AI-generated analysis. How Rhea-AI works. Not financial advice.
